Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

DNA vaccination.

Gordon Ada1, Ian Ramshaw

  • 1Division of Immunology and Genetics, John Curtin School of Medical Research, Australian National University, Canberra, ACT, Australia. gordon.ada@anu.edu.au

Expert Opinion on Emerging Drugs
|November 13, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Internal ribosome entry site-based attenuation of a flavivirus candidate vaccine and evaluation of the effect of beta interferon coexpression on vaccine properties.

Journal of virology·2013
Same author

The mousepox experience. An interview with Ronald Jackson and Ian Ramshaw on dual-use research. Interview by Michael J. Selgelid and Lorna Weir.

EMBO reports·2009
Same author

The enunciation and impact of Macfarlane Burnet's clonal selection theory of acquired immunity.

Immunology and cell biology·2008
Same author

Frank MacFarlane Burnet: two personal views.

Nature immunology·2007
Same author

The importance of vaccination.

Frontiers in bioscience : a journal and virtual library·2006
Same author

Overview of vaccines and vaccination.

Molecular biotechnology·2005
Same journal

σ<sub>1</sub> receptor agonists: the new trend or an emerging therapeutic option?

Expert opinion on emerging drugs·2026
Same journal

Obefazimod (ABX464) for moderate-to-severe Crohn's disease: clinical development of a novel oral therapeutic approach.

Expert opinion on emerging drugs·2026
Same journal

Evaluating emerging amyloid-β centric drugs for the treatment of Alzheimer's disease.

Expert opinion on emerging drugs·2026
Same journal

Emerging treatment options for chronic obstructive pulmonary disease: a look into 2026 and beyond.

Expert opinion on emerging drugs·2026
Same journal

Beyond triptans in menstrual migraine: the emerging role of CGRP-targeted therapies.

Expert opinion on emerging drugs·2026
Same journal

Acute management of adult MOG antibody-associated disease: therapeutic choices and clinical outcomes.

Expert opinion on emerging drugs·2026
See all related articles

DNA immunisation represents a rapid vaccine advancement, showing promise in clinical trials. This technology effectively activates immune cells, generating robust responses with a strong safety profile in human volunteers.

Area of Science:

  • Immunology
  • Vaccinology
  • Molecular Biology

Background:

  • DNA immunisation has progressed rapidly from discovery to clinical application.
  • The mechanism involves CpG-motif rich DNA recognition by dendritic cells (antigen-presenting cells [APCs]) leading to T lymphocyte activation.

Purpose of the Study:

  • To evaluate the immunogenicity and safety of DNA immunisation.
  • To explore the potential of DNA vaccines as adjuvants.

Main Methods:

  • Administration of chimaeric DNA to mice and primates.
  • Clinical trials involving several hundred human volunteers, including children.
  • Combination therapy using DNA priming followed by viral vector boosting.

Main Results:

Related Experiment Videos

  • Induction of both humoral and cell-mediated immune responses in preclinical models.
  • No significant safety concerns observed in human trials.
  • Generation of high avidity CD8+ cytotoxic T lymphocyte (CTL) responses in primates when boosted with viral vectors.
  • DNA as a potent adjuvant, primarily inducing T helper (Th)1 responses.

Conclusions:

  • DNA immunisation is a fast-developing vaccine technology with a favorable safety profile.
  • It elicits comprehensive immune responses and can be effectively combined with viral vectors for enhanced efficacy.
  • DNA vaccines offer advantages such as use in antibody-positive individuals and simplified manufacturing.